1 ; OF CALCIUM FROM PATIENT WHAT PHYSIC MUCU ON CF ARE EFFECT THE PROPERTI
2 ; BETWEEN HYPERSECRET OF INFECT RESPIRATORi IN AND SUBMUCOS MUCU ON DISTINGUISH CAN GLAND CF ONE EFFECT THE TRACT
3 ; FROM PATIENT OF GLYCOPROTEIN NORMAL HOW SALIVARi THOSE CF ARE DIFFER SUBJECT
4 ; OF WHAT RESPIRATORi IS SECRET LIPID CF COMPOSIT THE
5 ; ABNORM IS CF MUCU
6 ; OTHER PROPERTI VISCOS BRONCHIAL OF FROM PATIENT SPUTUM WHAT PHYSIC IS OR ON SECRET CF ELAST WATER EFFECT THERAPEUT THE AGENT
7 ; FROM PATIENT GLYCOPROTEIN AS DEGRAD IN NORMAL MUCU THOSE CF COMPAR ARE TO DIFFER SUBJECT
8 ; EPITHELIA BETWEEN BEEN WHAT NORMAL AND RESPIRATORi HISTOCHEM DESCRIB CF HAVE DIFFER
9 ; VITAMIN LIVER BETWEEN WHAT IN ASSOCI IS AND DISEAS CF METABOL THE CIRRHOSI
10 ; OF PATIENT WITH WHAT IN IS ROLE CF THERAPi THE VITAMIN
11 ; BETWEEN WHAT PLUG AND IS MECONIUM ILEU SYNDROM DIFFER THE
12 ; OF PATIENT BEEN SMALL WHAT IN AMINO TRANSPORT DESCRIB ABNORM CF BOWEL HAVE THE ACID
13 ; CLINIC OF PATIENT WHAT FEATUR IN BIOCHEM OR PANCREAT CF ARE THE
14 ; TEST OF BE PATIENT FOR WHAT EVALU IN WITH PERFORM CAN PANCREAT FUNCTION NON-INVAS CF EXOCRIN THE
15 ; MANIFEST OF WHAT HEPAT OR CF ARE THE COMPLIC
16 ; NEONAT LIVER OF EXCLUD GASTROINTESTIN WHAT AND MECONIUM AFTER DISEAS CF PERIOD ILEU ARE COMPLIC THE
17 ; REGIMEN OF PATIENT USE FOR WHAT ENZYM IN IS MOST SUPPLEMENT PANCREAT CF EFFECT THE TREATMENT
18 ; OF WITH PATIENT IS DIETARi SUPPLEMENT CF BILE SALT TO THERAPEUT BENEFIT
19 ; REPORT OF PATIENT BEEN ENZYM WHAT IN PANCREAT CF THERAPi HAVE COMPLIC
20 ; ACID OF PATIENT WITH WHAT IS SUPPLEMENT CF ESSENTI FATTi EFFECT THE TREATMENT
21 ; INSUFFICI AFFECT ABIL PATIENT IRON IN OR THEIR PANCREAT CF ABSORB METABOL DOE TO
22 ; POPUL OF FREQUENC WHAT IN IS CF NON-CAUCASIAN THE
23 ; WITH BEEN FOUND WHAT IN HEREDITARi ASSOCI CONDIT CONGENIT OR DISEAS CF HAVE
24 ; MANIFEST OF PATIENT WHAT IN IS CHARACTERIST CF INCOMPLET ARE THE WHOM
25 ; MORE GENE FOR WHAT THAN THERE IS GENET BASI INVOLV EVID THAT CF ONE THE
26 ; WHAT IN IS HETEROZYGOT ADVANTAG CF THE
27 ; WHOM CLINIC OF WHAT IN SIBL IS BIOCHEM BOTH OR CF PAIR CONCORD HAVE THE MANIFEST
28 ; OF INCID WHAT IN IS MALE CF FERTIL THE
29 ; FEMAL OF PATHOLOG REPRODUCT WHAT IN IS OR MALE SYSTEM CF THE
30 ; FAMILI OF WITH WHAT GENET CF ARE COUNSEL CHILDREN THE RESULT
31 ; OF PATIENT MAJOR WHAT SOCIAL AND OR ON THEIR PSYCHOLOG CF ARE EFFECT THE FAMILI
32 ; WITH PATIENT WHAT IN FACTOR INFLUENC PRESCRIB CF THERAPi COMPLIANC
33 ; TEST LEAD WHAT FACTOR CONDIT OR SWEAT ERRON TO
34 ; OTHER WHAT ADVANTAG SWEAT ALTERN PILOCARPIN OF TECHNIQU REL TEST WITH FOR ANALYSI AND CLASSIC QUANTIT ARE THE TITRIMETR CHLORID AVAIL THAN GIBSON-COOK THEIR IONTOPHORESI DISADVANTAG
35 ; TEST PATIENT BEEN FOUND NORMAL CONSIST CF ANi SWEAT HA TO HAVE
36 ; OF FROM PATIENT CONCENTR WHAT IN IS SWEAT POTASSIUM CF THE
37 ; OF TEST TECHNIQU WHAT AVAIL FOR SCREEN AND FACTOR NEWBORN CONTRIBUT CF ERRON ARE INFANT TO RESULT THESE
38 ; PRENAT DIAGNOS CAN CF BE
39 ; BE FOR HOW HETEROZYGOT IDENTIFI MAY CF
40 ; OTHER TEST OF BE USE TECHNIQU WHAT THAN FOR BEYOND DIAGNOSI MAY SWEAT CF PERIOD THE NEONAT
41 ; PATIENT NORMAL IN IS CF METABOL VITAMIN
42 ; OCCUR OF PATIENT INSULIN WHAT IN OR SECRET ABNORM METABOL CF
43 ; CHLORID IN IS AND/OR TRANSPORT/PERM ABNORM CF SALT SODIUM
44 ; BETWEEN NON-CF FROM PATIENT STRUCTUR WHAT THERE AND OR ENZYMAT CF FIBROBLAST ARE DIFFER
45 ; OF PATIENT BEEN WHAT IN PROSTAGLANDIN DESCRIB ABNORM METABOL CF HAVE
46 ; OF FROM PATIENT ENZYM WHAT ACTIV AND CF GALACTOSYLTRANSFERAS ARE THE PROPERTI
47 ; BETWEEN OF PATIENT BEEN WHAT NORMAL AND IN HORMON OR FUNCTION DESCRIB CF METABOL HAVE DIFFER SUBJECT THE
48 ; FROM PATIENT NORMAL RATE DO CF FIBROBLAST AT GROW
49 ; POLYAMIN PATIENT NORMAL IN IS METHYL OR CF METABOL RNA
50 ; OF PATIENT BEEN CYCLIC WHAT IN NUCLEOTID SYNTHESI DEFECT OR DESCRIB CF METABOL HAVE THE
51 ; WHAT FIBROSI FACTOR CF PLAY '' MOLECUL IN SOME THOUGHT DESCRIB CYSTIC UNIDENTIFI BIOLOG PATIENT BEEN ACTIV PATHOGENET `` OR ARE TO SECRET ROLE HAVE CIRCUL
52 ; PATIENT WHAT IN IS ABOUT CF KNOWN PROLACTIN
53 ; PATIENT INFECT COLON PROTECT AGAINST BACTERI OR SECRETORi CF DOE IGA
54 ; HYPERSENSIT LUNG OF PATIENT ALLERGi WHAT IN IS OR DISEAS CF TO RELATIONSHIP THE
55 ; BETWEEN ENDOGEN LUNG OF PATIENT WHAT ORIGIN AND IN BACTERI OR ANTIPROTEAS INTERACT CF ARE PROTEAS THE
56 ; BETWEEN INFECT PATIENT WHAT HOST AND IS DEFENS AGAINST BACTERI PULMONARi IN CF RELATIONSHIP THE NUTRIT
57 ; PATHOPHYSIOLOG OF PSEUDOMONA PATIENT AERUGINOSA WHAT IN IS ROLE ANTIBODI CF TO THE CIRCUL
58 ; RESPONS INFECT PATIENT IMMUNOLOG WHAT IN IS PULMONARi CF TO THE
59 ; PATIENT BEEN FOUND WHAT IMMUNOLOG IN ABNORM CF HAVE
60 ; OF WHAT ON PULMONARi CF ARE EFFECT THE CIRCUL
61 ; OF PATIENT RESPIRATORi IN THERE IS DEFECT TRANSPORT MUCOCILIARi CF CLEARANC THE TRACT
62 ; CLINIC LUNG OF PATIENT WHAT FEATUR IN DISEAS CF ARE THE
63 ; OF PATIENT WHAT IN BIOCHEM INFLAMM OR CHARACTERIST CF ARE AIRWAY THE MICROSCOP
64 ; TIME LUNG CHANG WITH PATIENT DAY IN HOW THAN GREATER FUNCTION CF DOE PERIOD
65 ; OF PATIENT WHAT IN PULMONARi FUNCTION ABNORM CF ARE THE
66 ; LUNG OF PATIENT PATHOLOG WHAT FEATUR IN DISEAS CF ARE THE
67 ; AN PATIENT OF PROGNOSI WHAT FOR RESPIRATORi IS FAILUR WHO EPISOD HAVE HAD THE
68 ; BRONCHODIL OF PATIENT WHAT IN CF ARE EFFECT THE
69 ; BEST PATIENT WHAT PNEUMOTHORAX TREAT IS IN CF WAY TO THE
70 ; OF PATIENT FOR WHAT PROGNOSI AND IS IN HEMOPTYSI CF THE TREATMENT
71 ; WITH WHEEZ PROGNOSI WHAT FOR AND IS FIBROSI INFANT CYSTIC THE
72 ; BEST PATIENT FOR WHAT IN IS POLYP NASAL CF THE TREATMENT
73 ; BRONCHIAL PATIENT IN HOW IS LAVAG CF EFFECT
74 ; OF PATIENT WITH WHAT IN RESPIRATORi CF FAILUR VENTIL MECHAN ARE THE RESULT
75 ; PULMONAL BEST PATIENT FOR WHAT IN IS AND/OR PULMONARi CF COR HYPERTENS THE TREATMENT
76 ; LUNG OF PATIENT WHAT IN ON FUNCTION CF TRAIN ARE EFFECT EXERCIS THE PROGRAM
77 ; LUNG OF FROM PATIENT TECHNIQU WHAT IN PROMOT MUCU CF CLEARANC ARE EFFECT THE
78 ; OTHER WHAT PHARMACODYNAM SPECIAL CF TREATMENT OF IN IE PATIENT WITH FOR PECULIAR ANTIBIOT OR PROBLEM ARE TO THE THERE DIFFER CONSIDER
79 ; OF PATIENT WHAT ANTIBIOT IN IS ORAL ADMINIST ROLE CF THE TREATMENT
80 ; AMINOGLYCOSID MORE WITH WHAT SEMISYNTHET AND IS THAN THAT EVID COMBIN THERAPi PENICILLIN EITHER EFFECT THE ALON
81 ; THE TREATMENT OF PATIENT IN HOW INHAL CF ARE EFFECT AGENT MUCOLYT
82 ; LUNG OF PATIENT WHAT IN IS AEROSOL DISEAS ROLE CF THE TREATMENT
83 ; LUNG OF PATIENT WHAT PHAGOCYTOSI IN IS BACTERI OR ALVEOLAR BY ROLE LEUKOCYT DISEAS MACROPHAG POLYMORPHONUCLEAR CF THE
84 ; BETWEEN PSEUDOMONA PATIENT AERUGINOSA WHAT IN AND IS HAEMOPHILU INFLUENZA CF RELATIONSHIP THE
85 ; OTHER IF ORGAN LUNG PATIENT INFECT SO WHAT IN THAN DEVELOP DO CF EVER THE
86 ; OTHER AUREU LUNG OF PSEUDOMONA BACTERIA PATIENT AERUGINOSA WHAT THAN IN IS PATHOGENESI STAPHYLOCOCCU HAEMOPHILU OR DISEAS ROLE INFLUENZA CF THE
87 ; LUNG OF PATIENT WHAT IN PATHOGENESI IS FUNGI DISEAS ROLE CF THE
88 ; LUNG OF INFECT PATIENT WHAT IN IS VIRAL DISEAS ROLE CF THE
89 ; OTHER EPIDEMIOLOG OF PSEUDOMONA PATIENT AERUGINOSA WHAT IN FAMILi IS OR DO SPREAD CF SPECIF TO THE INDIVIDU
90 ; RESPONS OF MUCOID PSEUDOMONA PATIENT FOR WHAT STRAIN AERUGINOSA FACTOR IN CF APPEAR ARE THE
91 ; OTHER INSUFFICI UNUSU OF LUNG WHAT THAN OR DISEAS PANCREAT CF ARE EXOCRIN THE MANIFEST
92 ; OF PATIENT WITH PROGNOSI WHAT FOR SURVIV IS CF THE
94 ; AVAIL WHAT ANIM MODEL RELEV CF WHICH ARE TO
95 ; OF PATIENT STRUCTUR BEEN WHAT FOUND IN OR FUNCTION ABNORM SKELET CF MUSCL HAVE
96 ; AN OF PATIENT INCID PERIODONT INCREAS THERE IS IN OR DISEAS CF EG PROBLEM DENTAL CARI
97 ; PATIENT OXYGEN IN IS TRANSPORT BY RED ABNORM CF BLOOD CELL
98 ; BRAIN OF WHAT AND CENTRAL AND/OR ON DEVELOP FUNCTION SYSTEM CF NERVOU ARE EFFECT THE
99 ; OF PATIENT TAST IN THERE ABNORM CF ARE
100 ; OSTEOARTHROPATHi OF PATIENT INCID FOR WHAT IN AND IS HYPERTROPH CF THE TREATMENT